Forestalling BRAF-inhibitor resistance in a shocking way

Abstract

Targeting BRAF in BRAF-mutant melanoma is highly effective, but most patients develop resistance. HSP90 has been implicated and identified as a therapeutic target. Ultimately, early-stage clinical investigation will be necessary to provide proof of principle of this approach and if appropriate randomized trials to confirm promising findings.